Agilent Technologies raises annual forecast after Q3 results beat on strong demand
Agilent Technologies raises annual forecast after Q3 results beat on strong demand
Overview
US analytical lab tech firm's Q3 revenue rose 8.1%, beating analyst expectations
Adjusted EPS for Q3 increased 18% and beat analyst expectations
Company raised FY26 revenue and non-GAAP EPS guidance on strong operational momentum
Outlook
Agilent raises FY26 revenue outlook to $7.49 bln-$7.51 bln, up 7.8%-8.1%
Company lifts FY26 non-GAAP EPS forecast to $6.18-$6.21
Agilent sees Q4 2026 revenue at $1.98 bln-$2.0 bln, non-GAAP EPS $1.71-$1.74
Result Drivers
SEGMENT GROWTH - All business segments reported year-over-year revenue growth, led by 11% growth in Life Sciences and Diagnostics Markets Group
END MARKET IMPROVEMENT - Co cited improving end markets and stronger demand in key regions as drivers of performance, per CEO Padraig McDonnell
TARIFF REFUNDS - Q3 margins and non-GAAP EPS benefited from a net benefit related to tariff refunds
Company press release: ID:nBwbFRlgKa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $1.88 bln | $1.84 bln (16 Analysts) |
Q3 Adjusted EPS | Beat | $1.62 | $1.49 (17 Analysts) |
Q3 EPS |
| $1.28 |
|
Q3 Adjusted Net Income | Beat | $459 mln | $419.71 mln (13 Analysts) |
Q3 Net Income |
| $362 mln |
|
Q3 Pretax Profit |
| $444 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Agilent Technologies Inc is $160.00, about 3.4% above its August 25 closing price of $154.77
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 18 three months ago
Reuters Recommended Reads
Aug 26 - Sweden's BPC Instruments Q2 sales fall on cautious customer decision-making
Aug 24 - Canada's Nanalysis Q2 revenue edges up on services strength
Aug 25 - McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)